JP2017502062A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017502062A5 JP2017502062A5 JP2016545782A JP2016545782A JP2017502062A5 JP 2017502062 A5 JP2017502062 A5 JP 2017502062A5 JP 2016545782 A JP2016545782 A JP 2016545782A JP 2016545782 A JP2016545782 A JP 2016545782A JP 2017502062 A5 JP2017502062 A5 JP 2017502062A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- oral dosage
- weight
- pharmaceutically acceptable
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000006186 oral dosage form Substances 0.000 claims description 109
- 150000003839 salts Chemical class 0.000 claims description 55
- 239000000203 mixture Substances 0.000 claims description 47
- 239000000945 filler Substances 0.000 claims description 40
- 239000000654 additive Substances 0.000 claims description 31
- 239000007884 disintegrant Substances 0.000 claims description 26
- 230000000996 additive effect Effects 0.000 claims description 24
- 239000000314 lubricant Substances 0.000 claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 20
- 229920000642 polymer Polymers 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 18
- 239000002552 dosage form Substances 0.000 claims description 17
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 17
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 17
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 12
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 12
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 claims description 11
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 claims description 10
- 235000019359 magnesium stearate Nutrition 0.000 claims description 10
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 9
- 239000004349 Polyvinylpyrrolidone-vinyl acetate copolymer Substances 0.000 claims description 9
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 9
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 9
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 9
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 9
- 235000019448 polyvinylpyrrolidone-vinyl acetate copolymer Nutrition 0.000 claims description 9
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 8
- 239000011118 polyvinyl acetate Substances 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 7
- 229920001577 copolymer Polymers 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims description 7
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical group O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 6
- 229960001021 lactose monohydrate Drugs 0.000 claims description 6
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 6
- 239000008109 sodium starch glycolate Substances 0.000 claims description 6
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 5
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 5
- 229920002554 vinyl polymer Polymers 0.000 claims description 5
- 238000007907 direct compression Methods 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 229920005862 polyol Polymers 0.000 claims description 4
- 150000003077 polyols Chemical class 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010027406 Mesothelioma Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000007908 dry granulation Methods 0.000 claims description 2
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 229950008937 defactinib Drugs 0.000 claims 13
- FWLMVFUGMHIOAA-UHFFFAOYSA-N n-methyl-4-[[4-[[3-[methyl(methylsulfonyl)amino]pyrazin-2-yl]methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]benzamide Chemical compound C1=CC(C(=O)NC)=CC=C1NC1=NC=C(C(F)(F)F)C(NCC=2C(=NC=CN=2)N(C)S(C)(=O)=O)=N1 FWLMVFUGMHIOAA-UHFFFAOYSA-N 0.000 claims 13
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 8
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 8
- 206010066476 Haematological malignancy Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- RCHQNUQAHJNRBY-UHFFFAOYSA-N n-methyl-4-[[4-[[3-[methyl(methylsulfonyl)amino]pyrazin-2-yl]methylamino]-5-(trifluoromethyl)pyrimidin-2-yl]amino]benzamide;hydrochloride Chemical compound Cl.C1=CC(C(=O)NC)=CC=C1NC1=NC=C(C(F)(F)F)C(NCC=2C(=NC=CN=2)N(C)S(C)(=O)=O)=N1 RCHQNUQAHJNRBY-UHFFFAOYSA-N 0.000 description 75
- 239000012458 free base Substances 0.000 description 16
- 239000011230 binding agent Substances 0.000 description 12
- 238000001556 precipitation Methods 0.000 description 11
- 239000003112 inhibitor Substances 0.000 description 10
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 7
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 6
- 229920003084 Avicel® PH-102 Polymers 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229920001531 copovidone Polymers 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- 239000004368 Modified starch Substances 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 229960000913 crospovidone Drugs 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 229960001375 lactose Drugs 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000019426 modified starch Nutrition 0.000 description 3
- 239000007962 solid dispersion Substances 0.000 description 3
- 229920003135 Eudragit® L 100-55 Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- FYUWIEKAVLOHSE-UHFFFAOYSA-N ethenyl acetate;1-ethenylpyrrolidin-2-one Chemical compound CC(=O)OC=C.C=CN1CCCC1=O FYUWIEKAVLOHSE-UHFFFAOYSA-N 0.000 description 2
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 2
- 208000006178 malignant mesothelioma Diseases 0.000 description 2
- 201000005282 malignant pleural mesothelioma Diseases 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- -1 Soluplus Chemical compound 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- LUJQXGBDWAGQHS-UHFFFAOYSA-N ethenyl acetate;phthalic acid Chemical compound CC(=O)OC=C.OC(=O)C1=CC=CC=C1C(O)=O LUJQXGBDWAGQHS-UHFFFAOYSA-N 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 229920002744 polyvinyl acetate phthalate Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461925467P | 2014-01-09 | 2014-01-09 | |
| US61/925,467 | 2014-01-09 | ||
| PCT/US2015/010810 WO2015106096A1 (en) | 2014-01-09 | 2015-01-09 | Compositions and methods for treatment of abnormal cell growth |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019168245A Division JP2020007355A (ja) | 2014-01-09 | 2019-09-17 | 異常な細胞成長を処置するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017502062A JP2017502062A (ja) | 2017-01-19 |
| JP2017502062A5 true JP2017502062A5 (OSRAM) | 2018-02-22 |
| JP6647204B2 JP6647204B2 (ja) | 2020-02-14 |
Family
ID=52434976
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016545782A Active JP6647204B2 (ja) | 2014-01-09 | 2015-01-09 | 異常な細胞成長を処置するための組成物および方法 |
| JP2019168245A Pending JP2020007355A (ja) | 2014-01-09 | 2019-09-17 | 異常な細胞成長を処置するための組成物および方法 |
| JP2021163957A Withdrawn JP2022001587A (ja) | 2014-01-09 | 2021-10-05 | 異常な細胞成長を処置するための組成物および方法 |
| JP2023030912A Withdrawn JP2023065568A (ja) | 2014-01-09 | 2023-03-01 | 異常な細胞成長を処置するための組成物および方法 |
| JP2025031469A Pending JP2025084892A (ja) | 2014-01-09 | 2025-02-28 | 異常な細胞成長を処置するための組成物および方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019168245A Pending JP2020007355A (ja) | 2014-01-09 | 2019-09-17 | 異常な細胞成長を処置するための組成物および方法 |
| JP2021163957A Withdrawn JP2022001587A (ja) | 2014-01-09 | 2021-10-05 | 異常な細胞成長を処置するための組成物および方法 |
| JP2023030912A Withdrawn JP2023065568A (ja) | 2014-01-09 | 2023-03-01 | 異常な細胞成長を処置するための組成物および方法 |
| JP2025031469A Pending JP2025084892A (ja) | 2014-01-09 | 2025-02-28 | 異常な細胞成長を処置するための組成物および方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20150190346A1 (OSRAM) |
| EP (2) | EP3091981B1 (OSRAM) |
| JP (5) | JP6647204B2 (OSRAM) |
| KR (3) | KR20240159639A (OSRAM) |
| CN (3) | CN115708827A (OSRAM) |
| AU (4) | AU2015204597B2 (OSRAM) |
| BR (1) | BR112016016021B1 (OSRAM) |
| CA (1) | CA2936283C (OSRAM) |
| DK (1) | DK3091981T3 (OSRAM) |
| ES (1) | ES2870562T3 (OSRAM) |
| IL (2) | IL246667B (OSRAM) |
| MX (2) | MX384259B (OSRAM) |
| NZ (2) | NZ721934A (OSRAM) |
| SG (2) | SG10201805890QA (OSRAM) |
| WO (1) | WO2015106096A1 (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019218958A1 (zh) * | 2018-05-15 | 2019-11-21 | 江苏豪森药业集团有限公司 | 包含小分子egfr抑制剂的药物组合物及其制备方法 |
| WO2021047783A1 (en) * | 2019-09-13 | 2021-03-18 | The Institute Of Cancer Research: Royal Cancer Hospital | Vs-6063 in combination with ch5126766 for the treatment of cancer |
| US20230201185A1 (en) * | 2020-03-27 | 2023-06-29 | Pfizer Inc. | Treatment of type 2 diabetes or obesity or overweight with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof |
| US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
| WO2024037498A1 (zh) * | 2022-08-15 | 2024-02-22 | 海创药业股份有限公司 | 一种治疗卵巢癌的联合用药物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE364374T1 (de) * | 1997-08-11 | 2007-07-15 | Pfizer Prod Inc | Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit |
| WO2005011634A1 (en) * | 2003-08-04 | 2005-02-10 | Pfizer Products Inc. | Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors |
| WO2006061712A2 (en) * | 2004-12-10 | 2006-06-15 | Pfizer Inc. | Use of mek inhibitors in treating abnormal cell growth |
| ES2593486T3 (es) | 2007-04-18 | 2016-12-09 | Pfizer Products Inc. | Derivados de sulfonil amida para el tratamiento del crecimiento celular anómalo |
| CN102231990B (zh) * | 2008-08-13 | 2013-09-25 | 沃泰克斯药物股份有限公司 | N-[2，4-双(1，1-二甲基乙基)-5-羟基苯基]-1，4-二氢-4-氧代喹啉-3-甲酰胺的药物组合物和其给药 |
| WO2011112922A2 (en) * | 2010-03-11 | 2011-09-15 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical formulations comprising the same |
| WO2012027247A2 (en) * | 2010-08-23 | 2012-03-01 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof |
| CN103491964A (zh) * | 2011-03-08 | 2014-01-01 | 扎里卡斯药品有限公司 | 固体分散体制剂及其使用方法 |
| EP2572731A1 (en) * | 2011-09-26 | 2013-03-27 | Abbott GmbH & Co. KG | Formulations based on solid dispersions |
| ES2945387T3 (es) * | 2014-02-07 | 2023-06-30 | Verastem Inc | Procedimientos y composiciones para tratar el crecimiento celular anormal |
| CA2991044C (en) * | 2015-06-29 | 2024-11-19 | Verastem, Inc. | THERAPEUTIC COMPOSITIONS, COMBINATIONS AND METHODS OF USE |
-
2015
- 2015-01-09 AU AU2015204597A patent/AU2015204597B2/en active Active
- 2015-01-09 US US14/593,468 patent/US20150190346A1/en not_active Abandoned
- 2015-01-09 KR KR1020247035735A patent/KR20240159639A/ko active Pending
- 2015-01-09 DK DK15701875.5T patent/DK3091981T3/da active
- 2015-01-09 ES ES15701875T patent/ES2870562T3/es active Active
- 2015-01-09 NZ NZ721934A patent/NZ721934A/en unknown
- 2015-01-09 CN CN202211274002.0A patent/CN115708827A/zh active Pending
- 2015-01-09 BR BR112016016021-5A patent/BR112016016021B1/pt active IP Right Grant
- 2015-01-09 WO PCT/US2015/010810 patent/WO2015106096A1/en not_active Ceased
- 2015-01-09 CN CN202411889753.2A patent/CN119868364A/zh active Pending
- 2015-01-09 KR KR1020167021370A patent/KR102444494B1/ko active Active
- 2015-01-09 NZ NZ760233A patent/NZ760233A/en unknown
- 2015-01-09 SG SG10201805890QA patent/SG10201805890QA/en unknown
- 2015-01-09 SG SG11201605588YA patent/SG11201605588YA/en unknown
- 2015-01-09 KR KR1020227031505A patent/KR20220130251A/ko not_active Ceased
- 2015-01-09 MX MX2016009056A patent/MX384259B/es unknown
- 2015-01-09 EP EP15701875.5A patent/EP3091981B1/en active Active
- 2015-01-09 CA CA2936283A patent/CA2936283C/en active Active
- 2015-01-09 JP JP2016545782A patent/JP6647204B2/ja active Active
- 2015-01-09 CN CN201580011527.7A patent/CN106102744A/zh active Pending
- 2015-01-09 EP EP21160977.1A patent/EP3900726A1/en active Pending
-
2016
- 2016-07-07 IL IL246667A patent/IL246667B/en unknown
- 2016-07-08 MX MX2021008225A patent/MX2021008225A/es unknown
-
2019
- 2019-03-11 US US16/298,907 patent/US20200038331A1/en not_active Abandoned
- 2019-09-17 JP JP2019168245A patent/JP2020007355A/ja active Pending
-
2020
- 2020-07-27 AU AU2020210153A patent/AU2020210153B2/en active Active
-
2021
- 2021-10-05 JP JP2021163957A patent/JP2022001587A/ja not_active Withdrawn
-
2022
- 2022-04-07 IL IL292054A patent/IL292054A/en unknown
- 2022-06-10 US US17/837,891 patent/US20230104303A1/en active Pending
- 2022-10-19 AU AU2022256144A patent/AU2022256144B2/en active Active
-
2023
- 2023-03-01 JP JP2023030912A patent/JP2023065568A/ja not_active Withdrawn
-
2025
- 2025-02-28 JP JP2025031469A patent/JP2025084892A/ja active Pending
- 2025-06-26 AU AU2025204843A patent/AU2025204843A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12403140B2 (en) | Pharmaceutical compositions of nilotinib | |
| DK2588086T3 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING 4-AMINO-5-FLUORO-3- [6- (4-METHYLPIPERAZIN-1-YL) -1H-BENZIMIDAZOL-2-YL] -1H-QUINOLIN-2-ON-LACTATE MONOHYDRATE | |
| CN105848647B (zh) | 包含azd9291的药用组合物 | |
| CN103550190A (zh) | 含有碱性药物或其盐的基质型缓释制剂 | |
| JP2017222705A5 (OSRAM) | ||
| EP1501485A1 (en) | High drug load tablet | |
| JP2017502062A5 (OSRAM) | ||
| CN103945831A (zh) | 医药制剂 | |
| EP3041511A2 (en) | Compositions of eltrombopag | |
| JP2017523149A (ja) | エドキサバンの医薬組成物 | |
| AU2016231883B2 (en) | Pharmaceutical compositions of dimethyl fumarate | |
| EP3925601B1 (en) | Gastro-resistant formulation containing posaconazole and a polymeric precipitation inhibitor | |
| MX2013000827A (es) | Composicion de tableta de unidad multiple. | |
| WO2010120963A1 (en) | Tablet formulation for p38 inhibitor and method | |
| EP2839829B1 (en) | Sustained release tablet containing levodropropizine and method for preparing same | |
| WO2015063670A1 (en) | Solid oral modified-release composition comprising oxcarbazepine or a pharmaceutically acceptable salt thereof | |
| CN104487057A (zh) | 波生坦控释口服制剂 | |
| WO2014030172A2 (en) | Pharmaceutical formulations of rufinamide | |
| JP5525453B2 (ja) | 医薬組成物 | |
| JP6812104B2 (ja) | 経口固形組成物 | |
| WO2025003956A1 (en) | High drug loading formulations of encorafenib | |
| KR20160141045A (ko) | 보센탄을 함유한 약학적 조성물 | |
| FI3843702T3 (fi) | Memantiinin ja donepetsiilin välittömästi vapauttava vakioannoksinen yhdistelmä | |
| KR20200048516A (ko) | 복합제 의약 조성물 | |
| WO2017163268A2 (en) | A sustained release pharmaceutical dosage form of divalproex |